Sutro Biopharma

Sutro Biopharma is focused on developing next-generation antibody-drug conjugates (ADCs) using its innovative cell-free platform. Targeting patients with cancer, Sutro's technology enhances drug exposure and minimizes side effects, with a unique capability in dual-payload ADCs that addresses treatment resistance. The company is advancing a promising pipeline aimed at large oncology markets that need better therapeutic options.